At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of stage IIIA or IIIB non-small cell lung cancer
- ✓Complete response, partial response, or stable disease after definitive locoregional therapy (surgery and/or radiation, with or without chemotherapy)
- ✓No more than 16 weeks since prior therapy
- ✓No progressive disease
- ✕Other malignancy within the past 3 years (except nonmelanoma skin cancer)
- ✕Pregnant or nursing
- ✕Prior cranial irradiation
- ✕Concurrent anticancer biologic therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating Radiation therapy and Observation for Lung Cancer. Completed, enrolled 356 participants across 14 sites.
Detailed Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head works in preventing CNS metastases in patients who have been previously treated for stage III non-small cell lung cancer.
Study Details
Timeline
Interventions
PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.